Structural Insight into Signal Conversion and Inactivation by NTPDase2 in Purinergic Signaling
Overview
Authors
Affiliations
Cell surface-located nucleoside triphosphate diphosphohydrolases (NTPDase1, -2, -3, and -8) are oligomeric integral membrane proteins responsible for signal conversion and inactivation in extracellular nucleotide-mediated "purinergic" signaling. They catalyze the sequential hydrolysis of the signaling molecule ATP via ADP to AMP. Here we present the structure of the extracellular domain of Rattus norvegicus NTPDase2 in an active state at resolutions between 1.7 A and 2.1 A in four different forms: (i) apo form, (ii) ternary complex with the nonhydrolyzable ATP analog AMPPNP and cofactor Ca(2+), (iii) quaternary complex with Ca(2+) and bound products AMP and phosphate, and (iv) binary product complex with AMP only. Analysis of the ATP (analog) binding mode explains the importance of several residues for activity and allows suggestion of a catalytic mechanism. The carboxylate group of E165 serves as a catalytic base and activates a water molecule, which is well positioned for nucleophilic attack on the terminal phosphate. Based on analysis of the two product complex structures in which AMP adopts different conformations, a substrate binding mode for ADP hydrolysis is proposed. This allows for an understanding of how the same hydrolytic site can be engaged in ATP and ADP but not AMP hydrolysis.
da Rocha Torres Pavione N, Badaro de Moraes J, Ribeiro I, Castro R, da Silva W, de Souza A Purinergic Signal. 2023; 20(5):509-520.
PMID: 37999896 PMC: 11377403. DOI: 10.1007/s11302-023-09980-9.
Ribeiro I, Badaro de Moraes J, Mariotini-Moura C, Poleto M, da Rocha Torres Pavione N, Castro R Purinergic Signal. 2023; 20(4):399-419.
PMID: 37975950 PMC: 11303637. DOI: 10.1007/s11302-023-09974-7.
Zaigham Z, Ullah S, Pelletier J, Sevigny J, Iqbal J, Hassan A RSC Adv. 2023; 13(30):20909-20915.
PMID: 37441049 PMC: 10335114. DOI: 10.1039/d3ra03874b.
Overexpression of Gene Increases Infectivity in Mice Infected with .
Silva-Gomes N, Ruivo L, Moreira C, Meuser-Batista M, da Silva C, Batista D Int J Mol Sci. 2022; 23(23).
PMID: 36498985 PMC: 9736689. DOI: 10.3390/ijms232314661.
Aleixo de Carvalho L, de Souza V, Rodrigues V, Ribeiro A, Nascimento J, Capriles P Pharmaceutics. 2022; 14(5).
PMID: 35631657 PMC: 9143675. DOI: 10.3390/pharmaceutics14051071.